(Total Views: 387)
Posted On: 03/18/2020 3:43:55 PM
Post# of 154115
Re: I_luv_cydy #22009
This is what I was referring to. I just put in a buy order at .88 but the price hasn't come back yet. The article below could be the reason for the late surge by CYDY as the overall market is still way down.
<
Newer -Swipe- Older
>
CytoDyn Inc CYDY
Posted On: 03/18/2020 2:19:03 PM
Post# of 22009

Replies (0)
Posted By: Rubraquercus
A Compassionate Use Study of Leronlimab in Breast Cancer
ClinicalTrials.gov Identifier: NCT04313075
Expanded Access Status : Available
First Posted : March 18, 2020
Last Update Posted : March 18, 2020
Detailed Description:
This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.
Leronlimab (PRO 140) will be administered subcutaneously as weekly dose of 350 mg until disease progression or intolerable toxicity. Treatment of Physician's Choice (TPC) is defined as one of the following single-agent chemotherapy drugs administrated according to local practice: eribulin, gemcitabine, capecitabine, paclitaxel, nab-paclitaxel, vinorelbine, ixabepilone, or carboplatin. The selected treatment should be administered as per the dosing schedule included on the package insert.
In this study, patients will be evaluated for tumor response approximately every 3 months or according to institution's standard practice by CT, PET/CT or MRI with contrast (per treating investigator's discretion) using the same method as at baseline. Tumor measurements will be done using RECIST v1.1.
https://clinicaltrials.gov/ct2/show/NCT043130...amp;rank=1
<
Newer -Swipe- Older
>
CytoDyn Inc CYDY
Posted On: 03/18/2020 2:19:03 PM
Post# of 22009

Replies (0)
Posted By: Rubraquercus
A Compassionate Use Study of Leronlimab in Breast Cancer
ClinicalTrials.gov Identifier: NCT04313075
Expanded Access Status : Available
First Posted : March 18, 2020
Last Update Posted : March 18, 2020
Detailed Description:
This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.
Leronlimab (PRO 140) will be administered subcutaneously as weekly dose of 350 mg until disease progression or intolerable toxicity. Treatment of Physician's Choice (TPC) is defined as one of the following single-agent chemotherapy drugs administrated according to local practice: eribulin, gemcitabine, capecitabine, paclitaxel, nab-paclitaxel, vinorelbine, ixabepilone, or carboplatin. The selected treatment should be administered as per the dosing schedule included on the package insert.
In this study, patients will be evaluated for tumor response approximately every 3 months or according to institution's standard practice by CT, PET/CT or MRI with contrast (per treating investigator's discretion) using the same method as at baseline. Tumor measurements will be done using RECIST v1.1.
https://clinicaltrials.gov/ct2/show/NCT043130...amp;rank=1
(0)
(0)
